What Is It?
The original non-steroidal SARM. Aryl-propionamide structure. Developed by GTx, Inc. in 2001. If YK-11 is the imposter in the SARM catalog — Ostarine is the prototype.
How Does It Work?
Tissue-selective androgen receptor agonism. Oral with a 24-hour half-life. Selectively targets muscle and bone over prostate tissue. Increases lean body mass (validated across 15+ trials) and improves bone mineral density.
Primary Benefits (research suggests)
- Lean body mass increases validated across 15+ trials
- Now in Phase 3 for AR+ breast cancer and as a muscle-preserving adjunct to GLP-1 weight loss drugs
- Potentially the most commercially relevant SARM application
Run the Numbers
Calculate your Ostarine dosing — capsule strength, daily totals, and protocol planning. Free, no login required.
Open the Calculator →The Honest Part
- The mildest SARM still isn't mild.
- Documented cholestatic jaundice cases.
- Suppresses testosterone.
- Not FDA-approved.
- WADA banned.
- Contaminated supply is rampant — Ryan Garcia's 2024 accidental ban is one example.
- For research purposes only.
Research Sources
Verified vendors offering this compound for research purposes. Use the vendor-specific code shown on each card for discounts. We may earn commissions from these links.
Track Ostarine in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →